126 related articles for article (PubMed ID: 10984261)
41. Auxological and endocrine evolution of 28 children with Prader-Willi syndrome: effect of GH therapy in 14 children.
Tauber M; Barbeau C; Jouret B; Pienkowski C; Malzac P; Moncla A; Rochiccioli P
Horm Res; 2000; 53(6):279-87. PubMed ID: 11146368
[TBL] [Abstract][Full Text] [Related]
42. A comprehensive team approach to the management of patients with Prader-Willi syndrome.
Eiholzer U; Whitman BY
J Pediatr Endocrinol Metab; 2004 Sep; 17(9):1153-75. PubMed ID: 15506675
[TBL] [Abstract][Full Text] [Related]
43. The efficacy and safety of long-term Norditropin® treatment in children with Prader-Willi syndrome.
Meinhardt U; Christiansen JS; Farholt S; Lämmer C; Ostergaard JR; Schmidt F; Kappelgaard AM; Eiholzer U
Horm Metab Res; 2013 Jul; 45(7):532-6. PubMed ID: 23632904
[TBL] [Abstract][Full Text] [Related]
44. Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: experience from KIGS (Pfizer International Growth Database).
Lindgren AC; Lindberg A
Horm Res; 2008; 70(3):182-7. PubMed ID: 18663319
[TBL] [Abstract][Full Text] [Related]
45. The effect of growth hormone on the response of total and acylated ghrelin to a standardized oral glucose load and insulin resistance in children with Prader-Willi syndrome.
Hauffa BP; Haase K; Range IM; Unger N; Mann K; Petersenn S
J Clin Endocrinol Metab; 2007 Mar; 92(3):834-40. PubMed ID: 17192298
[TBL] [Abstract][Full Text] [Related]
46. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.
Bakker NE; Lindberg A; Heissler J; Wollmann HA; Camacho-Hübner C; Hokken-Koelega AC;
J Clin Endocrinol Metab; 2017 May; 102(5):1702-1711. PubMed ID: 28323917
[TBL] [Abstract][Full Text] [Related]
47. Benefit of early commencement of growth hormone therapy in children with Prader-Willi syndrome.
Nyunt O; Harris M; Hughes I; Huynh T; Davies PS; Cotterill AM
J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1151-8. PubMed ID: 20333875
[TBL] [Abstract][Full Text] [Related]
48. Adults with Prader-Willi syndrome have weaker bones: effect of treatment with GH and sex steroids.
Longhi S; Grugni G; Gatti D; Spinozzi E; Sartorio A; Adami S; Fanolla A; Radetti G
Calcif Tissue Int; 2015 Feb; 96(2):160-6. PubMed ID: 25577526
[TBL] [Abstract][Full Text] [Related]
49. [Prader-Willi syndrome. Treatment with growth hormone in 2 cases].
Youlton R
Rev Med Chil; 2001 Oct; 129(10):1186-90. PubMed ID: 11775347
[TBL] [Abstract][Full Text] [Related]
50. Association between foot growth and musculoskeletal loading in children with Prader-Willi syndrome before and during growth hormone treatment.
Eiholzer U; Meinhardt U; Gallo C; Schlumpf M; Rousson V; l'Allemand D
J Pediatr; 2009 Feb; 154(2):225-9. PubMed ID: 18822426
[TBL] [Abstract][Full Text] [Related]
51. Five-years growth hormone (GH) treatment in adults with Prader-Willi syndrome.
Höybye C
Acta Paediatr; 2007 Mar; 96(3):410-3. PubMed ID: 17407467
[TBL] [Abstract][Full Text] [Related]
52. Effects of growth hormone in Prader-Willi syndrome.
Connor EL; Rosenbloom A
Clin Pediatr (Phila); 1993 May; 32(5):296-7. PubMed ID: 8324973
[No Abstract] [Full Text] [Related]
53. Brief Report: Repetitive Behaviour Profiles in Williams syndrome: Cross Syndrome Comparisons with Prader-Willi and Down syndromes.
Royston R; Oliver C; Moss J; Adams D; Berg K; Burbidge C; Howlin P; Nelson L; Stinton C; Waite J
J Autism Dev Disord; 2018 Jan; 48(1):326-331. PubMed ID: 28980100
[TBL] [Abstract][Full Text] [Related]
54. Growth hormone therapy, muscle thickness, and motor development in Prader-Willi syndrome: an RCT.
Reus L; Pillen S; Pelzer BJ; van Alfen-van der Velden JA; Hokken-Koelega AC; Zwarts M; Otten BJ; Nijhuis-van der Sanden MW
Pediatrics; 2014 Dec; 134(6):e1619-27. PubMed ID: 25422026
[TBL] [Abstract][Full Text] [Related]
55. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
[TBL] [Abstract][Full Text] [Related]
56. Growth hormone treatment downregulates serum leptin levels in children independent of changes in body mass index.
Elimam A; Lindgren AC; Norgren S; Kamel A; Skwirut C; Bang P; Marcus C
Horm Res; 1999; 52(2):66-72. PubMed ID: 10681635
[TBL] [Abstract][Full Text] [Related]
57. Approach to the child with prader-willi syndrome.
Miller JL
J Clin Endocrinol Metab; 2012 Nov; 97(11):3837-44. PubMed ID: 23129592
[No Abstract] [Full Text] [Related]
58. Fatal outcome of sleep apnoea in PWS during the initial phase of growth hormone treatment. A case report.
Eiholzer U; Nordmann Y; L'Allemand D
Horm Res; 2002; 58 Suppl 3():24-6. PubMed ID: 12435892
[TBL] [Abstract][Full Text] [Related]
59. Growth hormone secretion decreases with age in paediatric Prader-Willi syndrome.
Cohen M; Harrington J; Narang I; Hamilton J
Clin Endocrinol (Oxf); 2015 Aug; 83(2):212-5. PubMed ID: 25495188
[TBL] [Abstract][Full Text] [Related]
60. Growth hormone therapy for syndromic disorders.
Kelnar CJ
Clin Endocrinol (Oxf); 2003 Jul; 59(1):12-21. PubMed ID: 12807497
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
